Akari Therapeutics Plc ADR [NASDAQ: AKTX] traded at a low on 2025-12-02, posting a -14.10 loss after which it closed the day’ session at $0.35.
The results of the trading session contributed to over 16240729 shares changing hands. Over the past one week, the price volatility of Akari Therapeutics Plc ADR stands at 28.22% while the volatility over the past one month is 16.41%.
The market cap for AKTX stock reached $11.26 million, with 32.61 million shares outstanding and 32.48 million shares in the current float. Compared to the average trading volume of 344.98K shares, AKTX reached a trading volume of 16240729 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Akari Therapeutics Plc ADR [AKTX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AKTX shares is $4.53 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AKTX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Akari Therapeutics Plc ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 18, 2025. While these analysts kept the previous recommendation, B. Riley FBR raised their target price from $2.50 to $3. The new note on the price target was released on January 04, 2019, representing the official price target for Akari Therapeutics Plc ADR stock. Previously, the target price had yet another raise to $3, while B. Riley FBR Inc. analysts kept a Neutral rating on AKTX stock.
The Price to Book ratio for the last quarter was 0.50, with the Price to Cash per share for the same quarter was set at 0.08.
How has AKTX stock performed recently?
Akari Therapeutics Plc ADR [AKTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -21.87. With this latest performance, AKTX shares dropped by -53.95% in over the last four-week period, additionally sinking by -74.23% over the last 6 months – not to mention a drop of -71.69% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AKTX stock in for the last two-week period is set at 27.50, with the RSI for the last a single of trading hit 0.0885, and the three-weeks RSI is set at 0.0822 for Akari Therapeutics Plc ADR [AKTX]. The present Moving Average for the last 50 days of trading for this stock 0.7400, while it was recorded at 0.4252 for the last single week of trading, and 1.0206 for the last 200 days.
Akari Therapeutics Plc ADR (AKTX) Capital Structure & Debt Analysis
According to recent financial data for Akari Therapeutics Plc ADR. ( AKTX), the Return on Equity (ROE) stands at -196.60%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -65.35%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Akari Therapeutics Plc ADR’s Return on Invested Capital (ROIC) is -69.30%, showcasing its effectiveness in deploying capital for earnings.
Akari Therapeutics Plc ADR (AKTX) Efficiency & Liquidity Metrics
Based on Akari Therapeutics Plc ADR’s (AKTX) latest financial statements, the Debt-to-Equity Ratio is 0.09%, indicating its reliance on debt financing relative to shareholder equity.
Akari Therapeutics Plc ADR (AKTX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Akari Therapeutics Plc ADR. (AKTX) effectively leverages its workforce, generating an average of -$1746666.67 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.19% and a Quick Ratio of 0.19%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Akari Therapeutics Plc ADR [AKTX]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AKTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Akari Therapeutics Plc ADR go to 37.15%.
Insider trade positions for Akari Therapeutics Plc ADR [AKTX]
There are presently around $3.31%, or 4.83%% of AKTX stock, in the hands of institutional investors. The top three institutional holders of AKTX stocks are: OMNIA FAMILY WEALTH, LLC with ownership of 87628.0 shares, which is approximately 26827.8123%. CERITY PARTNERS LLC, holding 23643.0 shares of the stock with an approximate value of $$63836.0 in AKTX stocks shares; and CERITY PARTNERS LLC, currently with $$49702.0 in AKTX stock with ownership which is approximately 5635.7143%.
